DISEASE CHARACTERISTICS: - Patients must have had a previous histological verification of rhabdomyosarcoma at original diagnosis - Patients with first relapse or progression of rhabdomyosarcoma are eligible - Patients with primary refractory disease are eligible - Patients with botryoid histology, any stage or group, are ineligible - Patients with embryonal histology, stage I or clinical group 1 at initial disease presentation, who present with local or regional recurrence, are ineligible - Patients without measurable or evaluable disease are eligible - Bone marrow disease involvement of tumor is allowed, however, peripheral blood count criteria must still be met - Patients with known CNS disease, except for those with treated brain metastasis, are ineligible - Treated brain metastases are defined as having no ongoing requirement for steroids and no evidence of progression or hemorrhage after treatment for at least 3 months, as ascertained by clinical examination and brain imaging (MRI or CT) - Stable dose of anticonvulsants are allowed - Treatment for brain metastases may include whole-brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent), or a combination as deemed appropriate by the treating physician - Patients with CNS metastases treated within 3 months prior to enrollment by neurosurgical resection or brain biopsy are ineligible PATIENT CHARACTERISTICS: - Patients must have a Karnofsky or Lansky performance status score of ≥ 50%, corresponding to ECOG categories of 0, 1, or 2 - Use Karnofsky for patients > 16 years of age and Lansky for patients ≤ 16 years of age - Patients must have a life expectancy of ≥ 8 weeks - Peripheral absolute neutrophil count (ANC) ≥ 750/μL - Platelet count ≥ 75,000/μL (transfusion independent, defined as without transfusion for ≥ 1 week prior to enrollment) - Hemoglobin ≥ 8.0 g/dL (may receive PRBC transfusions) - Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m^2 OR a serum creatinine based on age/gender as follows: - ≤ 0.4 mg/dL (for patients aged 1 month to < 6 months) - ≤ 0.5 mg/dL (for patients aged 6 months to < 1 year) - ≤ 0.6 mg/dL (for patients aged 1 to < 2 years) - ≤ 0.8 mg/dL (for patients aged 2 to < 6 years) - ≤ 1 mg/dL (for patients aged 6 to < 10 years) - ≤ 1.2 mg/dL (for patients aged 10 to < 13 years) - ≤ 1.4 mg/dL (for female patients aged ≥ 13 years) - ≤ 1.5 mg/dL (for male patients aged 13 to < 16 years) - ≤ 1.7 mg/dL (for male patients aged ≥ 16 years) - Urine protein level: - For patients aged ≤ 17 years, UPC ratio must be ≤ 1 for patient to be eligible - For patients aged > 17 years, urine protein should be screened by urine analysis; if protein is 2+ or higher, 24-hour urine protein must be obtained and the level must be < 1000 mg for patient enrollment - Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception for the duration of study participation - Patients with a documented chronic non-healing wound, ulcer, or significant trauma injury (those with bone fractures, including pathological fractures, or requiring surgical intervention) within 28 days prior to beginning therapy are ineligible - Patients with evidence of intratumoral hemorrhage, gastrointestinal bleeding, or on anticoagulation for thrombosis or history of thrombosis are ineligible - Patients with uncontrolled hypertension are ineligible; uncontrolled hypertension is defined as follows: - Patients aged ≤ 17 years: greater than 95th percentile systolic and diastolic blood pressure based on age and height that is not controlled by one antihypertensive medication - Patients aged > 17 years: systolic blood pressure ≥ 160 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg that is not controlled by one antihypertensive medication - Patients with history of central venous catheter (CVC)-associated thrombosis requiring systemic anticoagulation are ineligible - NOTE: Patients with history of sluggish flow from CVC or CVC-associated thrombosis treated with tissue plasminogen activator (TPA) only are not excluded. - Patients with clinically significant cardiovascular disease are excluded: - History of cerebrovascular accident (CVA) within the prior 6 months - Myocardial infarction or unstable angina within the prior 6 months - New York Heart Association grade 2 or greater congestive heart failure - Serious and inadequately controlled cardiac arrhythmia - Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) - Clinically significant peripheral vascular disease PRIOR CONCURRENT THERAPY: - See Disease Characteristics - Patients who previously received vinorelbine, bevacizumab, temsirolimus, or any other direct VEGF/VEGFR- or mTOR- targeting agents are ineligible - Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study - For autologous stem cell transplantation (SCT), ≥ 3 months must have elapsed - For allogeneic SCT, ≥ 6 months must have elapsed and no evidence of active graft vs host disease - 3 half-lives (or 6 weeks) must have elapsed since previous monoclonal antibody therapy prior to enrollment on this study - At least 4 weeks must have elapsed between radiotherapy and study entry - Patients who previously received craniospinal irradiation are ineligible - Previously radiated lesions cannot be used to assess response unless those sites are the sites of disease progression - No myelosuppressive chemotherapy within 3 weeks prior to entry onto this study (4 weeks if prior nitrosourea) - Patients may have received prior therapy with oral tyrosine kinase inhibitors or other similar agents - At least 7 days must have elapsed since the completion of therapy with a biologic agent and all toxicities must have resolved to < grade 2 prior to enrollment - No myeloid growth factor within 1 week prior to entry onto this study - Patients must have recovered from any surgical procedure before enrolling on this study - Minor surgical procedures (e.g., biopsies involving core or fine-needle aspiration procedures, infusaport or Broviac line placement, paracentesis, or thoracocentesis) need to have fully healed and occurred > 7 days prior to enrollment - Patients who have had a major surgical procedure (such as laparotomy, thoracotomy, open biopsy, or resection of tumor) can only be enrolled on study > 28 days from such procedure - Patients currently taking anticoagulants or antiplatelet agents with the exception of aspirin (≤ 81 mg/day) are ineligible - Patients may not undergo surgery or radiotherapy during the first 2 courses (6 weeks) of therapy